Phocas Financial Corp. Sells 195,023 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Phocas Financial Corp. trimmed its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 85.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,528 shares of the company's stock after selling 195,023 shares during the quarter. Phocas Financial Corp.'s holdings in Elanco Animal Health were worth $418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Blue Trust Inc. grew its holdings in Elanco Animal Health by 2,129.2% in the 3rd quarter. Blue Trust Inc. now owns 3,968 shares of the company's stock worth $57,000 after acquiring an additional 3,790 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Elanco Animal Health by 70.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 19,515 shares of the company's stock worth $287,000 after purchasing an additional 8,077 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Elanco Animal Health by 158.7% in the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock worth $49,000 after purchasing an additional 2,044 shares during the last quarter. Private Management Group Inc. increased its holdings in Elanco Animal Health by 62.6% during the 3rd quarter. Private Management Group Inc. now owns 1,442,334 shares of the company's stock valued at $21,188,000 after purchasing an additional 555,131 shares during the period. Finally, Harbor Capital Advisors Inc. increased its holdings in Elanco Animal Health by 101.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 874,895 shares of the company's stock valued at $12,852,000 after purchasing an additional 439,757 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Up 2.7 %

Elanco Animal Health stock traded up $0.30 on Friday, hitting $11.22. 3,775,852 shares of the stock traded hands, compared to its average volume of 4,864,694. Elanco Animal Health Incorporated has a 1 year low of $10.20 and a 1 year high of $18.80. The firm has a market cap of $5.54 billion, a P/E ratio of 28.12, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The business's fifty day simple moving average is $11.72 and its 200 day simple moving average is $13.05.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the business earned $0.08 earnings per share. The company's revenue was down 1.4% on a year-over-year basis. As a group, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on ELAN. Stifel Nicolaus dropped their price objective on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. Leerink Partners assumed coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price target for the company. UBS Group reduced their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday. Morgan Stanley dropped their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday. Finally, Barclays cut their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of "Hold" and an average target price of $15.83.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.